Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Operating activities
Net loss	$ (31,380)	$ (36,825)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	158	113
Stock-based compensation	3,404	2,450
Non-cash research and development expenses		20,000
Non-cash lease expense	232	217
Changes in fair value of derivative liability		1,100
Changes in operating assets and liabilities:
License receivable		(8,000)
Prepaid expenses and other assets	(232)	(71)
Other assets, noncurrent	(340)
Accounts payable	(9,896)	(447)
Accrued expenses and other current liabilities	10,540	(491)
Operating lease liabilities	(165)	(146)
Derivative liability		3,369
Net cash used in operating activities	(27,679)	(18,731)
Investing activities
Purchase of property and equipment	(146)	(169)
Investment in joint venture		(50)
Net cash used in investing activities	(146)	(219)
Financing activities
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs		151,581
Deferred offering costs		(47)
Proceeds from the exercise of stock options	176
Net cash provided by financing activities	176	151,534
Net (decrease) increase in cash, cash equivalents, and restricted cash	(27,649)	132,584
Cash, cash equivalents and restricted cash at beginning of year	276,316	8,188
Cash, cash equivalents and restricted cash at end of year	248,667	140,772
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	247,087	140,663
Restricted cash	1,580	109
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 248,667	$ 140,772